Eugenia M. Yazlovitskaya

Dr. Eugenia M. Yazlovitskaya


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2010 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
ALAmanda G. Linkous
Amanda G. Linkous
EYEugenia M. Yazlovitskaya
Eugenia M. Yazlovitskaya
DHDennis E. Hallahan
Dennis E. Hallahan
Lung cancer and glioblastoma multiforme are highly angiogenic and, despite advances in treatment, remain resistant to therapy. Cytosolic phospholipase A2 (cPLA 2 ) activation contributes to treatment resistance through transduction of prosurvival signals. We investigated cPLA 2 as a novel molecular target for antiangiogenesis therapy. Glioblastoma (GL261) and Lewis lung carcinoma (LLC) heterotopic tumor models were used to study the effects of cPLA 2 expression on tumor growth and vascularity in C57/BL6 mice wild type for (cPLA 2 α +/+ ) or deficient in (cPLA 2 α −/− ) cPLA 2 α, the predominant isoform in endothelium (n = 6–7 mice per group). The effect of inhibiting cPLA 2 activity on GL261 and LLC tumor growth was studied in mice treated with the chemical cPLA 2 inhibitor 4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1 H -indol-3-yl]-ethoxy]benzoic acid (CDIBA). Endothelial cell proliferation and function were evaluated by Ki-67 immunofluorescence and migration assays in primary cultures of murine pulmonary microvascular endothelial cells (MPMEC) isolated from cPLA 2 α +/+ and cPLA 2 α −/− mice. Proliferation, invasive migration, and tubule formation were assayed in mouse vascular endothelial 3B-11 cells treated with CDIBA. Effects of lysophosphatidylcholine, arachidonic acid, and lysophosphatidic acid (lipid mediators of tumorigenesis and angiogenesis) on proliferation and migration were examined in 3B-11 cells and cPLA 2 α −/− MPMEC. All statistical tests were two-sided. GL261 tumor progression proceeded normally in cPLA 2 α +/+ mice, whereas no GL261 tumors formed in cPLA 2 α −/− mice. In the LLC tumor model, spontaneous tumor regression was observed in 50% of cPLA 2 α −/− mice. Immunohistochemical examination of the remaining tumors from cPLA 2 α −/− mice revealed attenuated vascularity ( P ≤ .001) compared with tumors from cPLA 2 α +/+ mice. Inhibition of cPLA 2 activity by CDIBA resulted in a delay in tumor growth (eg, LLC model: average number of days to reach tumor volume of 700 mm 3 , CDIBA vs vehicle: 16.8 vs 11.8, difference = 5, 95% confidence interval = 3.6 to 6.4, P = .04) and a decrease in tumor size (eg, GL261 model: mean volume on day 21, CDIBA vs vehicle: 40.1 vs 247.4 mm 3 , difference = 207.3 mm 3 , 95% confidence interval = 20.9 to 293.7 mm 3 , P = .021). cPLA 2 deficiency statistically significantly reduced MPMEC proliferation and invasive migration ( P = .002 and P = .004, respectively). Compared with untreated cells, cPLA 2 α −/− MPMEC treated with lysophosphatidylcholine and lysophosphatidic acid displayed increased cell proliferation ( P = .011) and invasive migration ( P < .001). In these mouse models of brain and lung cancer, cPLA 2 and lysophospholipids have key regulatory roles in tumor angiogenesis. cPLA 2 inhibition may be a novel effective antiangiogenic therapy.

14 July 2010 in Cellular Microbiology
Verified
Journal Article
Closed access
PDF file
ALAmanda Linkous
Amanda Linkous
EYEugenia M. Yazlovitskaya
Eugenia M. Yazlovitskaya
As efficient catalysts, enzymes help maintain a variety of biological and chemical transformations necessary for cellular metabolism and normal physiology. Unfortunately, pathogenic microbes can also exploit enzymatic reactions in an attempt to spread infection. Cytosolic phospholipase A2 (cPLA(2) ) is an enzyme that is responsible for the hydrolysis of membrane phospholipids such as phosphatidylcholine. Following activation, cPLA(2) cleaves phosphatidylcholine to yield free fatty acid and lysophosphatidylcholine. Both of these products and their downstream metabolites initiate a network of signalling cascades that influence cellular viability and inflammation. Recent observations have shown that viral and bacterial agents often target this intricate organization of signalling molecules. This review briefly discusses the role of cPLA(2) in the biological response to disease-causing pathogens and injury, the immunological process and tumour progression.

1 February 2010 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
DTDinesh K. Thotala
Dinesh K. Thotala
LGLing Geng
Ling Geng
ADAmy K. Dickey
Amy K. Dickey
DHDennis E. Hallahan
Dennis E. Hallahan
EYEugenia M. Yazlovitskaya
Eugenia M. Yazlovitskaya

27 February 2009 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ALAmanda Linkous
Amanda Linkous
LGLing Geng
Ling Geng
ALAndrej Lyshchik
Andrej Lyshchik
DHDennis E. Hallahan
Dennis E. Hallahan
EYEugenia M. Yazlovitskaya
Eugenia M. Yazlovitskaya
Purpose: In vascular endothelial cells, low doses of ionizing radiation trigger the immediate activation of cytosolic phospholipase A2 (cPLA2). This event initiates prosurvival signaling that could be responsible for radioresistance of tumor vasculature. Thus, the development of radiosensitizers targeting these survival pathways may enhance tumor response to radiation therapy. Arachidonyltrifluoromethyl Ketone (AACOCF3), a specific cPLA2 inhibitor, was studied as a potential radiosensitizer. Experimental Design: Vascular endothelial cells (3B11 and MPMEC) and lung tumor cells (LLC and H460) were treated with 1 μmol/L AACOCF3 for 30 minutes prior to irradiation. Treatment response was evaluated by clonogenic survival, activation of extracellular signal-regulated kinase 1/2 (ERK1/2), tubule formation, and migration assays. For in vivo experiments, mice with LLC or H460 tumors in the hind limbs were treated for 5 consecutive days with 10 mg/kg AACOCF3 administered daily 30 minutes prior to irradiation. Treatment response was assessed by tumor growth delay, Power Doppler Sonography, and immunohistochemistry. Results: In cell culture experiments, inhibition of cPLA2 with AACOCF3 prevented radiation-induced activation of ERK1/2 and decreased clonogenic survival of irradiated vascular endothelial cells but not the lung tumor cells. Treatment with AACOCF3 also attenuated tubule formation and migration in irradiated vascular endothelial cells. In both tumor mouse models, treatment with AACOCF3 prior to irradiation significantly suppressed tumor growth and decreased overall tumor blood flow and vascularity. Increased apoptosis in both tumor cells and tumor vascular endothelium was determined as a possible mechanism of the observed effect. Conclusion: These findings identify cPLA2 as a novel molecular target for tumor sensitization to radiation therapy through the tumor vasculature.

8 July 2011 in Cell Death & Differentiation
Verified
Journal Article
Closed access
DTD K Thotala
D K Thotala
DHD E Hallahan
D E Hallahan
EYEugenia M. Yazlovitskaya
Eugenia M. Yazlovitskaya

1 September 2009 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
DTDinesh Thotala
Dinesh Thotala
SCSergei Chetyrkin
Sergei Chetyrkin
BHBilly Hudson
Billy Hudson
DHDennis Hallahan
Dennis Hallahan
PVPaul Voziyan
Paul Voziyan
EYEugenia M. Yazlovitskaya
Eugenia M. Yazlovitskaya